Cargando…
Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration
BACKGROUND: A protein exhibiting more than one biochemical function is termed a moonlighting protein. Glycolytic enzymes are typical moonlighting proteins, and these enzymes control the infection of various viruses. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and al...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488571/ https://www.ncbi.nlm.nih.gov/pubmed/32917235 http://dx.doi.org/10.1186/s12977-020-00539-9 |
_version_ | 1783581719549444096 |
---|---|
author | Kishimoto, Naoki Yamamoto, Kengo Iga, Nozomi Kirihara, Chie Abe, Towa Takamune, Nobutoki Misumi, Shogo |
author_facet | Kishimoto, Naoki Yamamoto, Kengo Iga, Nozomi Kirihara, Chie Abe, Towa Takamune, Nobutoki Misumi, Shogo |
author_sort | Kishimoto, Naoki |
collection | PubMed |
description | BACKGROUND: A protein exhibiting more than one biochemical function is termed a moonlighting protein. Glycolytic enzymes are typical moonlighting proteins, and these enzymes control the infection of various viruses. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and alpha-enolase (ENO1) are incorporated into human immunodeficiency virus type 1 (HIV-1) particles from viral producer cells and suppress viral reverse transcription independently each other. However, it remains unclear whether these proteins expressed in viral target cells affect the early phase of HIV-1 replication. RESULTS: Here we show that the GAPDH expression level in viral target cells does not affect the early phase of HIV-1 replication, but ENO1 has a capacity to suppress viral integration in viral target cells. In contrast to GAPDH, suppression of ENO1 expression by RNA interference in the target cells increased viral infectivity, but had no effect on the expression levels of the HIV-1 receptors CD4, CCR5 and CXCR4 and on the level of HIV-1 entry. Quantitative analysis of HIV-1 reverse transcription products showed that the number of copies of the late products (R/gag) and two-long-terminal-repeat circular forms of viral cDNAs did not change but that of the integrated (Alu-gag) form increased. In contrast, overexpression of ENO1 in viral target cells decreased viral infectivity owing to the low viral integration efficiency. Results of subcellular fractionation experiments suggest that the HIV integration at the nucleus was negatively regulated by ENO1 localized in the nucleus. In addition, the overexpression of ENO1 in both viral producer cells and target cells most markedly suppressed the viral replication. CONCLUSIONS: These results indicate that ENO1 in the viral target cells prevents HIV-1 integration. Importantly, ENO1, but not GAPDH, has the bifunctional inhibitory activity against HIV-1 replication. The results provide and new insights into the function of ENO1 as a moonlighting protein in HIV-1 infection. |
format | Online Article Text |
id | pubmed-7488571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74885712020-09-16 Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration Kishimoto, Naoki Yamamoto, Kengo Iga, Nozomi Kirihara, Chie Abe, Towa Takamune, Nobutoki Misumi, Shogo Retrovirology Research BACKGROUND: A protein exhibiting more than one biochemical function is termed a moonlighting protein. Glycolytic enzymes are typical moonlighting proteins, and these enzymes control the infection of various viruses. Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and alpha-enolase (ENO1) are incorporated into human immunodeficiency virus type 1 (HIV-1) particles from viral producer cells and suppress viral reverse transcription independently each other. However, it remains unclear whether these proteins expressed in viral target cells affect the early phase of HIV-1 replication. RESULTS: Here we show that the GAPDH expression level in viral target cells does not affect the early phase of HIV-1 replication, but ENO1 has a capacity to suppress viral integration in viral target cells. In contrast to GAPDH, suppression of ENO1 expression by RNA interference in the target cells increased viral infectivity, but had no effect on the expression levels of the HIV-1 receptors CD4, CCR5 and CXCR4 and on the level of HIV-1 entry. Quantitative analysis of HIV-1 reverse transcription products showed that the number of copies of the late products (R/gag) and two-long-terminal-repeat circular forms of viral cDNAs did not change but that of the integrated (Alu-gag) form increased. In contrast, overexpression of ENO1 in viral target cells decreased viral infectivity owing to the low viral integration efficiency. Results of subcellular fractionation experiments suggest that the HIV integration at the nucleus was negatively regulated by ENO1 localized in the nucleus. In addition, the overexpression of ENO1 in both viral producer cells and target cells most markedly suppressed the viral replication. CONCLUSIONS: These results indicate that ENO1 in the viral target cells prevents HIV-1 integration. Importantly, ENO1, but not GAPDH, has the bifunctional inhibitory activity against HIV-1 replication. The results provide and new insights into the function of ENO1 as a moonlighting protein in HIV-1 infection. BioMed Central 2020-09-11 /pmc/articles/PMC7488571/ /pubmed/32917235 http://dx.doi.org/10.1186/s12977-020-00539-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kishimoto, Naoki Yamamoto, Kengo Iga, Nozomi Kirihara, Chie Abe, Towa Takamune, Nobutoki Misumi, Shogo Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
title | Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
title_full | Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
title_fullStr | Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
title_full_unstemmed | Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
title_short | Alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
title_sort | alpha-enolase in viral target cells suppresses the human immunodeficiency virus type 1 integration |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488571/ https://www.ncbi.nlm.nih.gov/pubmed/32917235 http://dx.doi.org/10.1186/s12977-020-00539-9 |
work_keys_str_mv | AT kishimotonaoki alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration AT yamamotokengo alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration AT iganozomi alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration AT kiriharachie alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration AT abetowa alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration AT takamunenobutoki alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration AT misumishogo alphaenolaseinviraltargetcellssuppressesthehumanimmunodeficiencyvirustype1integration |